Genetic Technologies Joins US-Based CancerIQ Platform; Shares Up 8%
Genetic Technologies (ASX:GTG) joined the Chicago-based CancerIQ platform, giving it access to the US healthcare system, according to a Wednesday filing with the Australian bourse.
As part of the move, Genetic Technologies will pay an annual fee of $75,000 to access CancerIQ's premium tier, the filing stated. This will give the molecular diagnostics company an entry point to over 45 health systems and 250 clinics in the US that are part of CancerIQ's platform.
The partnership includes the addition of Genetic Technologies' geneType risk assessment test portfolio to support CancerIQ's expansion into primary preventive care.
Genetic Technologies' shares were up nearly 8% in recent trade.
Price (AUD): $0.04, Change: $+0.0030, Percent Change: +7.50%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。